An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Norway Core Inflation Rises to 3% in August
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
Japan Producer Inflation Eases to 7.6% in August
Hyundai Delays In-House ADAS, Turns to Nvidia
Nvidia Eyes $10 Billion Investment in Anthropic IPO
Asian Stocks Slide as Oil Surge Fuels Rate Hike Fears
BOJ Set to Raise Rates to 1.25% as Inflation Risks Build
German Inflation Accelerates to 2.9% in August
OpenAI Rules Out 2026 IPO as Altman Prioritizes AI Safety
AstraZeneca, Bristol Myers Squibb Explore Mega Merger Worth Nearly $400 Billion
Volkswagen Job Cuts Put Lower Saxony Leader Under Political Pressure
Central Banks Could Buy 20,000 Tonnes of Gold: BofA
Can Europe shake its Russia links for good?
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations
OpenAI Targets Specialized Industries as Enterprise AI Demand Grows
SpaceX Nasdaq 100 Weight Set to More Than Double
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 



